Announcements Trials
Browse Landscape

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1Breast Diseases 1Breast Carcinoma In Situ 1

Interventions

Fulvestrant 63Letrozole 53Paclitaxel 49Trastuzumab 41pembrolizumab 40ribociclib 37Specimen Handling 37palbociclib 36Capecitabine 34Carboplatin 33Anastrozole 33Tamoxifen 32exemestane 29pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 24Surveys and Questionnaires 21Radiotherapy 18Biopsy 18olaparib 17Standard of Care 16Docetaxel 16Blood Specimen Collection 16Taxes 14Mastectomy, Segmental 14eribulin 13elacestrant 13130-nm albumin-bound paclitaxel 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Genotype × 90 days × Clear all
NCT05006196 2026-05-20

IMOGEN

Perspectum

Active not recruiting
1,030 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT05755269 2026-05-01

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

Mayo Clinic

Terminated
19 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡